Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
Trial details
- Registry ID
- NCT04678830
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as PRO 140; Pro140
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19NCT04678830 | CytoDyn, Inc. | Phase 2 | Completed | 2021-06-05Actual |
| Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19NCT04347239 | CytoDyn, Inc. | Phase 2 | Completed | 2021-10-24Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |